Literature DB >> 1545778

Molecular conformation of estramustine and two analogues.

J S Punzi1, W L Duax, P Strong, J F Griffin, M M Flocco, D E Zacharias, H L Carrell, K D Tew, J P Glusker.   

Abstract

The crystal and molecular structures of estramustine and two of its analogues have been determined by X-ray crystallographic techniques (a total of three different compounds). The compounds studied are estramustine [1,3,5(10)-estratriene-3,17 beta-diol-3-N,N-bis(2'- chloroethyl)carbamate] and its monohydrate, estromustine [17-oxo-1,3,5(10)-estratriene-3-yl-N,N-bis(2'-chloroethyl)carbamate], and 17-oxo-5-androsten-3 beta-yl-N,N-bis(2'-chloroethyl)carbamate. Three views of estramustine were obtained from the study of its two crystal forms. The main structural features found are as follows: (a) the geometries of the steroid moieties are closely similar to those of the parent steroids, (b) the bonds around the nitrogen atom of the nitrogen mustard grouping lie approximately in a plane in each structure, (c) the plane through the carbon atoms of the steroid A-ring lies approximately perpendicular to the plane through the carbamate atoms in each structure, (d) the carbonyl C-O of the carbamate points to the alpha side of the steroid moiety in each structure, and (e) one chlorine atom of the nitrogen mustard grouping makes a close contact [3.13 A], in each structure, to the nitrogen atom. Hydrogen bonding to the carbamate appears to occur from the alpha side of the steroid; there is no hydrogen bonding to the nitrogen atom of the carbamate group. These structural data provide some steric explanations for the resistance of the carbamate to enzymatic hydrolysis. The long in vivo half-life of the intact estramustine molecule is a result of this stability. This is responsible for the absence of alkylating ability and the propensity of the drug to bind microtubule-associated proteins and express an antimitotic mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1545778

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration.

Authors:  Jody T Mack; Kristi L Helke; Gabrielle Normand; CoDanielle Green; Danyelle M Townsend; Kenneth D Tew
Journal:  Cancer Lett       Date:  2010-10-30       Impact factor: 8.679

Review 2.  ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target.

Authors:  Warren Davis; Kenneth D Tew
Journal:  Biochem Pharmacol       Date:  2017-12-06       Impact factor: 5.858

3.  Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

Authors:  Howard Landy; Arnold Markoe; Priscilla Potter; Garrett Lasalle; Angela Marini; Niramol Savaraj; Isildinha Reis; Deborah Heros; Medhi Wangpaichitr; Lynn Feun
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 4.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

5.  Evaluation of lipophilins as determinants of tumor cell response to estramustine.

Authors:  Jody M Tucker; Zhanna Lipatova; Vladimir Beljanski; Danyelle M Townsend; Kenneth D Tew
Journal:  J Pharmacol Exp Ther       Date:  2005-08-24       Impact factor: 4.030

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.